Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.52 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.52 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806938 | 0.88 | MAP2K1 (0.52) | MAP2K1MAP2K2MAP2K5EIF2AK1ABCB1 | |
| SCHEMBL3010504 | 0.84 | MAP2K1 (0.58) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL16366765 | 0.82 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2720642 | 0.82 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL486804 | 0.81 | MAP2K1 (0.69) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2718815 | 0.81 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1ABCB1 | |
| SCHEMBL486396 | 0.81 | MAP2K1 (0.72) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL18487396 | 0.80 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2718749 | 0.80 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL10118289 | 0.80 | MAP2K1 (0.48) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011095807-A1 | COMBINATIONS OF MEK AND HH INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-11 | — | — | WO | disclosed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100130519-A1 | COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100004247-A1 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MAP2K1 23/4885MAP2K2 19/4885MAP2K5 28/4885 |
| US-20100130519-A1 | COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II | MAP2K2, MAP3K21, BRAF | MAP2K1 11/4885MAP2K2 1/4885MAP2K5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.